Clinical observations on the use of the muscle relaxant rocuronium bromide in the dog

Vet J. 2007 Mar;173(2):422-7. doi: 10.1016/j.tvjl.2005.11.014. Epub 2006 Jan 19.

Abstract

This study was designed to evaluate the effectiveness of neuromuscular blockade with rocuronium bromide (rocuronium) in eighty dogs anaesthetised for a variety of surgical procedures. Rocuronium 0.3 or 0.6 mg/kg (G03 and G06) was administered intravenously (IV) and neuromuscular function was monitored with an acceleromyograph. Lag time (LT) was >1 min in both groups. Onset time (OT) was 2+/-0.9 and 1.1+/-0.6 min in the groups given 0.3 and 0.6 mg/kg, respectively. There was a significantly longer time of action with 0.6 mg/kg in contrast to 0.3 mg/kg rocuronium. Time of no response (TonR) was 9.1+/-4.9-16.9+/-6.1 min in the groups given 0.3 and 0.6 mg/kg, respectively. The time from the end of injection until 25% recovery of the first twitch from the baseline value (T1(25)) was 13.8+/-5.5 and 22.3+/-6.7 min in the groups given 0.3 and 0.6 mg/kg, respectively. T1(25-75) was similar in both groups. Total recovery to baseline values was achieved in 23.8+/-6.6 and 31.9+/-6.5 min in the groups given 0.3 and 0.6 mg/kg, respectively (P<0.05). Premedication, maintenance agent, body position and stimulation site had no significant influence on the pharmacodynamic parameters in both groups. It was concluded that rocuronium is an effective non-depolarising muscle relaxant in the dog under clinical conditions.

Publication types

  • Clinical Trial

MeSH terms

  • Androstanols / pharmacology*
  • Anesthesia, General / veterinary
  • Animals
  • Dog Diseases / surgery
  • Dogs
  • Dose-Response Relationship, Drug
  • Neuromuscular Agents / pharmacology*
  • Rocuronium
  • Time Factors

Substances

  • Androstanols
  • Neuromuscular Agents
  • Rocuronium